Bladder cancer

Current Opinion in Oncology

Volumn 14, Issue 3, 2002, Pages 265-272

  Patton, Suzanne E ^a   Hall, M Craig ^a   Ozen, Haluk ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GENE PRODUCT; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; NAVELBINE; PACLITAXEL; TUMOR MARKER; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; BLADDER CARCINOGENESIS; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG TOLERABILITY; GENE THERAPY; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYSTECTOMY; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; RADIOTHERAPY DOSAGE; URINARY BLADDER NEOPLASMS;

EID: 0036245473     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200205000-00003     Document Type: Review

References (55)

1. Global cancer statistics
2. Prospective study of dietary supplements, macronutrients, micronutrients, and the risk of bladder cancer in US men
3. Management of carcinoma of the bladder
4. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking
5. Epidemiology and prevention of bladder cancer
6. Use of permanent hair dyes and bladder cancer risk
7. De novo muscle invasive bladder cancer: Is there a change in trend?
8. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation
9. Expression of cyclooxygenase-2 in patients with bladder carcinoma
10. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder
11. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6132F1 mice and female Fischer-344 rats
12. Molecular genetic methods in the diagnosis of invasive bladder cancer
13. Filling the void: Urinary markers for bladder cancer
14. Comparative predictive values of urinary bladder cancer antigen, Cyfra 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer
15. Current bladder tumor tests: Does their projected utility fulfill clinical necessity?
16. Urine detection of survivin and diagnosis of bladder cancer
17. Molecular analysis of urine sediment for follow-up of urinary tract cancers
18. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder
19. Phase 1 study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer
20. Does early cystectomy improve the survival of the patients with high risk bladder tumors?
21. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early?
22. Clinical understaging of high risk nonmuscle invasive uretheliai carcinoma treated with radical cystectomy
23. Nerve and seminal sparing radical cystectomy with orthotopic urinary diversion for select patients with superficial bladder cancer: An innovative surgical approach
24. Sexuality preserving cystectomy and neobladder: Initial results
25. Laparoscopic radical cystectomy with continent urinary diversion (rectal sigmoid pouch) performed completely intracorporeally: The initial 5 cases
26. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
27. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy
28. Upper-tract tumors after an initial diagnosis of bladder cancer: Argument for long-term surveillance
29. Radiotherapy for carcinoma of the bladder
30. Planned preoperative radiation therapy in muscle invasive bladder cancer: Results of a meta-analysis
31. Long-term follow-up of a phase III Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
32. Gemcitabine in advanced bladder cancer
33. Significant activity of paclitaxel in advanced carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (E1892)
34. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An eastern cooperative oncology group study
35. Phase II trial of paclitaxel and cisplatin in advanced urothelial cancer (UC)
36. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial
37. Docetaxel and ifosfamide as second line treatment fro patients with advanced of metastatic urothelial cancer after failure of platinum chemotherapy: A phase 2 study
38. Carboplatin-based chemotherapy for bladder cancer
39. Palliative chemotherapy with gemcitabine (Gem) and carboplatin (CBDCA) in advanced transitional cell carcinoma of the urothelium (ATCCU) preliminary results
40. A dose finding study of carboplatin with fixed doses of gemcitabine in 'unfit' patients with advanced bladder cancer
41. Recent developments in chemotherapy for bladder cancer
42. E2896 paclitaxel (P)/carboplatin © in advanced urothelial carcinoma and renal insufficiency: A phase II trial of the Eastern Cooperative Oncology Group (ECOG)
43. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma (TCC) of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network
44. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium
45. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant
46. Neoadjuvant CMV chemotherapy and cystectomy or radiation in muscle-invasive bladder cancer: First analysis of MRC/EORTC intercontinental trial
47. Cisplatin, methotrexate and vinblastine (CMV) plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium
48. A randomized trial of radical cystectomy plus cisplatin, vinblastine, and methotrexate chemotherapy for muscle invasive bladder cancer
49. SWOG 8710 (INT-0080): Randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer
50. Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer
51. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: A five year follow-up
52. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: A southwest oncology group study
53. Effects of vitamin D (calcitriol) on the transitional cell carcinoma of the bladder in vitro and in vivo
54. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis